142 related articles for article (PubMed ID: 20447554)
1. Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer.
Menda Y; Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Gupta AK; Anderson C; McGuire S; Schultz MK; Sunderland JJ; Graham MM; Buatti JM
Nucl Med Biol; 2010 May; 37(4):433-8. PubMed ID: 20447554
[TBL] [Abstract][Full Text] [Related]
2. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy.
Menda Y; Boles Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Schultz MK; Sunderland JJ; Graham MM; Buatti JM
J Nucl Med; 2009 Jul; 50(7):1028-35. PubMed ID: 19525472
[TBL] [Abstract][Full Text] [Related]
3. 3'-deoxy-3'-[¹⁸F]fluorothymidine PET quantification of bone marrow response to radiation dose.
McGuire SM; Menda Y; Boles Ponto LL; Gross B; Buatti J; Bayouth JE
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):888-93. PubMed ID: 21300484
[TBL] [Abstract][Full Text] [Related]
4. Stability of 3'-deoxy-3'-[18F]fluorothymidine standardized uptake values in head and neck cancer over time.
Boles Ponto LL; Menda Y; Dornfeld K; Tewson TJ; Watkins GL; Sunderland J; Graham MM; Buatti J
Cancer Biother Radiopharm; 2010 Jun; 25(3):361-3. PubMed ID: 20578842
[TBL] [Abstract][Full Text] [Related]
5. Using [(18)F]Fluorothymidine Imaged With Positron Emission Tomography to Quantify and Reduce Hematologic Toxicity Due to Chemoradiation Therapy for Pelvic Cancer Patients.
McGuire SM; Bhatia SK; Sun W; Jacobson GM; Menda Y; Ponto LL; Smith BJ; Gross BA; Bayouth JE; Sunderland JJ; Graham MM; Buatti JM
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):228-39. PubMed ID: 27319286
[TBL] [Abstract][Full Text] [Related]
6. Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy.
Hoshikawa H; Mori T; Kishino T; Yamamoto Y; Inamoto R; Akiyama K; Mori N; Nishiyama Y
Ann Nucl Med; 2013 May; 27(4):363-70. PubMed ID: 23378102
[TBL] [Abstract][Full Text] [Related]
7. Effect of radiotherapy and chemotherapy on bone marrow activity: a 18F-FLT-PET study.
Agool A; Slart RH; Thorp KK; Glaudemans AW; Cobben DC; Been LB; Burlage FR; Elsinga PH; Dierckx RA; Vellenga E; Holter JL
Nucl Med Commun; 2011 Jan; 32(1):17-22. PubMed ID: 21166089
[TBL] [Abstract][Full Text] [Related]
8. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ
J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108
[TBL] [Abstract][Full Text] [Related]
9. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
[TBL] [Abstract][Full Text] [Related]
10. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome.
Hoeben BA; Troost EG; Span PN; van Herpen CM; Bussink J; Oyen WJ; Kaanders JH
J Nucl Med; 2013 Apr; 54(4):532-40. PubMed ID: 23345303
[TBL] [Abstract][Full Text] [Related]
11. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
Muzi M; Vesselle H; Grierson JR; Mankoff DA; Schmidt RA; Peterson L; Wells JM; Krohn KA
J Nucl Med; 2005 Feb; 46(2):274-82. PubMed ID: 15695787
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of 3'-deoxy-3'-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer.
Kishino T; Hoshikawa H; Nishiyama Y; Yamamoto Y; Mori N
J Nucl Med; 2012 Oct; 53(10):1521-7. PubMed ID: 22872738
[TBL] [Abstract][Full Text] [Related]
13. First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine.
Buck AK; Bommer M; Juweid ME; Glatting G; Stilgenbauer S; Mottaghy FM; Schulz M; Kull T; Bunjes D; Möller P; Döhner H; Reske SN
J Nucl Med; 2008 Nov; 49(11):1756-62. PubMed ID: 18927328
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
Muzi M; Spence AM; O'Sullivan F; Mankoff DA; Wells JM; Grierson JR; Link JM; Krohn KA
J Nucl Med; 2006 Oct; 47(10):1612-21. PubMed ID: 17015896
[TBL] [Abstract][Full Text] [Related]
15. Reproducibility of the kinetic analysis of 3'-deoxy-3'-[(18)F]fluorothymidine positron emission tomography in mouse tumor models.
Choi SJ; Kim SY; Kim SJ; Lee JS; Lee SJ; Park SA; Lee SJ; Yun SC; Im KC; Oh SJ; Kim SW; Kim JS; Ryu JS; Moon DH
Nucl Med Biol; 2009 Oct; 36(7):711-9. PubMed ID: 19720283
[TBL] [Abstract][Full Text] [Related]
16. 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment.
Agool A; Schot BW; Jager PL; Vellenga E
J Nucl Med; 2006 Oct; 47(10):1592-8. PubMed ID: 17015893
[TBL] [Abstract][Full Text] [Related]
17. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
18. FLT PET Radiomics for Response Prediction to Chemoradiation Therapy in Head and Neck Squamous Cell Cancer.
Ulrich EJ; Menda Y; Boles Ponto LL; Anderson CM; Smith BJ; Sunderland JJ; Graham MM; Buatti JM; Beichel RR
Tomography; 2019 Mar; 5(1):161-169. PubMed ID: 30854454
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma.
Inubushi M; Saga T; Koizumi M; Takagi R; Hasegawa A; Koto M; Wakatuki M; Morikawa T; Yoshikawa K; Tanimoto K; Fukumura T; Yamada S; Kamada T
Ann Nucl Med; 2013 Jan; 27(1):1-10. PubMed ID: 22914968
[TBL] [Abstract][Full Text] [Related]
20. Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of
Vercellino L; Ouvrier MJ; Barré E; Cassinat B; de Beco V; Dosquet C; Chevret S; Meignin V; Chomienne C; Toubert ME; Merlet P; Kiladjian JJ
J Nucl Med; 2017 Oct; 58(10):1603-1608. PubMed ID: 28360204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
